Genetic variations in multiple myeloma I: Effect on risk of multiple myeloma

European Journal of Haematology

Volumn 88, Issue 1, 2012, Pages 8-30

  Vangsted, Annette ^a   Klausen, Tobias W ^b   Vogel, Ulla ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT   (Denmark)

Author keywords

Multiple myeloma; Risk; SNP

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYCLOOXYGENASE 2; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA; FOLIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR ALPHA; INTERLEUKIN 12P35; INTERLEUKIN 16; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 8; INTERLEUKIN 8 RECEPTOR; METHIONINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PURINERGIC P2X7 RECEPTOR; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; XENOBIOTIC AGENT;

AMINO ACID METABOLISM; ANGIOGENESIS; APOPTOSIS; CANCER RISK; CELL CYCLE REGULATION; DNA METHYLATION; DNA REPAIR; DNA SYNTHESIS; FOLATE METABOLISM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INFLAMMATION; MULTIPLE MYELOMA; NONHUMAN; PATHOGENESIS; PLASMA CELL; PRIORITY JOURNAL; REVIEW;

DNA REPAIR; FEMALE; FOLIC ACID; GENE-ENVIRONMENT INTERACTION; GENETIC VARIATION; HUMANS; INFLAMMATION; MALE; METHIONINE; MULTIPLE MYELOMA; PLASMA CELLS; RISK FACTORS; XENOBIOTICS;

EID: 83655161361     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01700.x     Document Type: Review

References (113)

1. Ichii M, Shimazu T, Welner RS, Garrett KP, Zhang Q, Esplin BL, Kincade PW. Functional diversity of stem and progenitor cells with B-lymphopoietic potential. Immunol Rev 2010;237:10-21.
2. Hewitt SL, Chaumeil J, Skok JA. Chromosome dynamics and the regulation of V(D)J recombination. Immunol Rev 2010;237:43-54.
3. Puebla-Osorio N, Zhu C. DNA damage and repair during lymphoid development: antigen receptor diversity, genomic integrity and lymphomagenesis. Immunol Res 2008;41:103-22.
4. Vettermann C, Schlissel MS. Allelic exclusion of immunoglobulin genes: models and mechanisms. Immunol Rev 2010;237:22-42.
5. Oracki SA, Walker JA, Hibbs ML, Corcoran LM, Tarlinton DM. Plasma cell development and survival. Immunol Rev 2010;237:140-59.
6. Yoshida T, Mei H, Dorner T, Hiepe F, Radbruch A, Fillatreau S, Hoyer BF. Memory B and memory plasma cells. Immunol Rev 2010;237:117-39.
7. Yeung J, Chang H. Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma. J Clin Pathol 2008;61:832-6.
8. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489-95.
9. Yasui H, Hideshima T, Richardson PG, Anderson KC. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol 2006;132:385-97.
10. Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006;66:6675-82.
11. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009;374:324-39.
12. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007;138:563-79.
13. Hideshima T, Podar K, Chauhan D, Anderson KC. Cytokines and signal transduction. Best Pract Res Clin Haematol 2005;18:509-24.
14. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115-30.
15. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131-44.
16. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001;276:22382-7.
17. Hideshima T, Ikeda H, Chauhan D, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009;114:1046-52.
18. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002;99:4079-86.
19. González D, van der Burg M, García-Sanz R, Fenton JA, Langerak AW, González M, van Dongen JJ, San Miguel JF, Morgan GJ. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 2007;110:3112-21.
20. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
21. Bishop JM. The molecular genetics of cancer. Science 1987;235:305-11.
22. Shammas MA, Shmookler Reis RJ, Koley H, Batchu RB, Li C, Munshi NC. Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood 2009;113:2290-7.
23. Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, Trichopoulos D. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 2007;120(Suppl 12):40-61.
24. Ogmundsdóttir HM, Haraldsdóttirm V, Jóhannesson GM, Olafsdóttir G, Bjarnadóttir K, Sigvaldason H, Tulinius H. Familiality of benign and malignant paraproteinemias. A population-based cancer-registry study of multiple myeloma families. Haematologica 2005;90:66-71.
25. Crettol S, Petrovic N, Murray M. Pharmacogenetics of phase I and phase II drug metabolism. Curr Pharm Des 2010;16:204-19.
26. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.
27. Tucci M, Quatraro C, Dammacco F, Silvestris F. Role of active drug transporters in refractory multiple myeloma. Curr Top Med Chem 2009;9:218-24.
28. Lincz LF, Scorgie FE, Robertson R, Enno A. Genetic variations in benzene metabolism and susceptibility to multiple myeloma. Leuk Res 2007;31:759-63.
29. Lincz LF, Kerridge I, Scorgie FE, Bailey M, Enno A, Spencer A. Xenobiotic gene polymorphisms and susceptibility to multiple myeloma. Haematologica 2004;89:628-9.
30. Kang SH, Kim TY, Kim HY, Yoon JH, Cho HI, Yoon SS, Kang DH, Suh CW, Lee JH, Lee DS. Protective role of CYP1A1*2A in the development of multiple myeloma. Acta Haematol 2008;119:60-4.
31. Gold LS, De Roos AJ, Brown EE, et al. Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma. Cancer Epidemiol 2009;4:276-80.
32. Vangsted AJ, Soeby K, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Vogel U, Werge T, Rasmussen HB. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma. BMC Cancer 2010;10:404.
33. Ortega MM, Honma HN, Zambon L, Lorand-Metze I, Costa FF, De Souza CA, Lima CS GSTM1 and codon 72 P53 polymorphism in multiple myeloma. Ann Hematol 2007;86:815-9.
34. Maggini V, Buda G, Galimberti S, Martino A, Orciuolo E, Morabito F, Bono R, Barale R, Petrini M, Rossi AM. Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk. Leuk Res 2008;32:988-90.
35. Drain S, Catherwood MA, Orr N, Galligan L, Rea IM, Hodkinson C, Drake MB, Kettle PJ, Morris TC, Alexander HD. ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma. Leuk Lymphoma 2009;50:566-70.
36. Jamroziak K, Balcerczak E, Calka K, Piaskowski S, Urbanska-Rys H, Salagacka A, Mirowski M, Robak T. Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk Res 2009;33:332-5.
37. Smith EM, Boyd K, Davies FE. The potential role of epigenetic therapy in multiple myeloma. Br J Haematol 2010;148:702-13.
38. Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G, Wickramasinghe SN, Everson RB, Ames BN. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci U S A 1997;94:3290-5.
39. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
40. González Ordóñez AJ, Fernández Carreira JM, Fernández Alvarez CR, Martin L, Sánchez Garcia J, Medina Rodríguez JM, Alvarez MV, Coto E. Normal frequencies of the C677T genotypes on the methylenetetrahydrofolate reductase (MTHFR) gene among lymphoproliferative disorders but not in multiple myeloma. Leuk Lymphoma 2000;6:607-12.
41. González-Fraile MI, García-Sanz R, Mateos MV, Balanzategui A, González M, Váquez L, San Miguel JF. Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis. Br J Haematol 2002;117:890-2.
42. Lincz LF, Scorgie FE, Kerridge I, Potts R, Spencer A, Enno A. Methionine synthase genetic polymorphism MS A2756G alters susceptibility to follicular but not diffuse large B-cell non-Hodgkin's lymphoma or multiple myeloma. Br J Haematol 2003;120:1051-4.
43. Chiusolo P, Farina G, Putzulu R, Reddiconto G, Fiorini A, De Stefano V, Rossi E, Palladino M, Leone G, Sica S. Analysis of MTHFR polymorphisms and P16 methylation and their correlation with clinical-biological features of multiple myeloma. Ann Hematol 2006;85:474-7.
44. Moon HW, Kim TY, Oh BR, Min HC, Cho HI, Bang SM, Lee JH, Yoon SS, Lee DS. MTHFR 677CC/1298CC genotypes are highly associated with chronic myelogenous leukemia: a case-control study in Korea. Leuk Res 2007;31:1213-7.
45. Kim HN, Kim YK, Lee IK, Lee JJ, Yang DH, Park KS, Choi JS, Park MR, Jo DY, Kim HJ. Polymorphisms involved in the folate metabolizing pathway and risk of multiple myeloma. Am J Hematol 2007;82:798-801.
46. Zintzaras E, Giannouli S, Rodopoulou P, Voulgarelis M. The role of MTHFR gene in multiple myeloma. J Hum Genet 2008;53:499-507.
47. Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, Eydoux P, Rosenblatt DS, Rozen R, Gravel RA. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996;5:1867-74.
48. Lima CS, Ortega MM, Ozelo MC, Araujo RC, De Souza CA, Lorand-Metze I, Annichino-Bizzacchi JM, Costa FF. Polymorphisms of methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), methionine synthase reductase (MTRR), and thymidylate synthase (TYMS) in multiple myeloma risk. Leuk Res 2008;32:401-5.
49. de Boer J, Hoeijmakers JH. Nucleotide excision repair and human syndromes. Carcinogenesis 2000;21:453-60.
50. Trigiante G, Lu X. ASPP [corrected] and cancer. Nat Rev Cancer 2006;6:217-26.
51. Yang JP, Hori M, Sanda T, Okamoto T. Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor. J Biol Chem 1999;274:15662-70.
52. Bergamaschi D, Samuels Y, O'Neil NJ, et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 2003;33:162-7.
53. Laska MJ, Lowe SW, Zender L, Hearn S, Vogel U, Jensen UB, Bric A, Nexø BA. Enforced expression of PPP1R13L increases tumorigenesis and invasion through p53-dependent and p53-independent mechanisms. Mol Carcinog 2009;48:832-42.
54. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science 2001;291:1284-9.
55. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
56. Roddam PL, Rollinson S, O'Driscoll M, Jeggo PA, Jack A, Morgan GJ. Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. J Med Genet 2002;39:900-5.
57. Hayden PJ, Tewari P, Morris DW, et al. Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma. Hum Mol Genet 2007;16:3117-27.
58. Vangsted A, Gimsing P, Klausen TW, Nexo BA, Wallin H, Andersen P, Hokland P, Lillevang ST, Vogel U. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer 2007;120:1036-45.
59. Hosgood HD III, Baris D, Zhang Y, et al. Caspase polymorphisms and genetic susceptibility to multiple myeloma. Hematol Oncol 2008;26:148-51.
60. Hosgood HD III, Baris D, Zhang Y, et al. Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk. Leuk Res 2009;33:1609-14.
61. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-8.
62. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-6.
63. El Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.
64. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F, Bellvitge Colorectal Cancer Study Group. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 2003;63:3560-6.
65. Howell WM, Rose-Zerilli MJ. Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 2006;5:143-9.
66. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006;7:27-38.
67. Zhang X, Miao X, Tan W, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005;129:565-76.
68. Spink CF, Gray LC, Davies FE, Morgan GJ, Bidwell JL. Haplotypic structure across the I kappa B alpha gene (NFKBIA) and association with multiple myeloma. Cancer Lett 2007;2:92-9.
69. Frassanito MA, Cusmai A, Iodice G, Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001;97:483-9.
70. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15.
71. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, Anderson KC. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997;159:2212-21.
72. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001;20:5991-6000.
73. Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 1995;85:765-71.
74. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-76.
75. Cozen W, Gebregziabher M, Conti DV, et al. Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev 2006;15:2285-91.
76. Vangsted AJ, Klausen TW, Ruminski W, et al. The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant 2009;43:539-45.
77. Birmann BM, Tamimi RM, Giovannucci E, Rosner B, Hunter DJ, Kraft P, Mitsiades C, Anderson KC, Colditz GA. Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 2009;18:282-8.
78. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001;20:4519-27.
79. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997;94:3195-9.
80. Du J, Yuan Z, Zhang C, Fu W, Jiang H, Chen B, Hou J. Role of the TNF-alpha promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. Leuk Res 2010;34:1453-8.
81. Davies FE, Rollinson SJ, Rawstron AC, Roman E, Richards S, Drayson M, Child JA, Morgan GJ. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J Clin Oncol 2000;18:2843-51.
82. Morgan GJ, Adamson PJ, Mensah FK, et al. Haplotypes in the tumour necrosis factor region and myeloma. Br J Haematol 2005;129:358-65.
83. Brown EE, Lan Q, Zheng T, Zhang Y, Wang SS, Hoar-Zahm S, Chanock SJ, Rothman N, Baris D. Common variants in genes that mediate immunity and risk of multiple myeloma. Int J Cancer 2007;120:2715-22.
84. Kádár K, Kovács M, Karádi I, et al. Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res 2008;32:1499-504.
85. Zheng C, Huang DR, Bergenbrant S, Sundblad A, Osterborg A, Bjorkholm M, Holm G, Yi Q. Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 2000;109:39-45.
86. Aladzsity I, Kovacs M, Semsei A, Falus A, Szilagyi A, Karadi I, Varga G, Füst G, Várkonyi J. Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma. Leuk Res 2009;33:1570-3.
87. Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Raaschou-Nielsen O, Overvad K, Tjønneland A. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res 2008;2:89-100.
88. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I. The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br J Haematol 1990;74:424-31.
89. Kline M, Donovan K, Wellik L, et al. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leuk Res 2007;31:591-8.
90. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
91. Chen H, Wilkins LM, Aziz N, et al. Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet 2006;15:519-29.
92. Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, Yamaoka Y. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology 2002;123:1793-803.
93. Abazis-Stamboulieh D, Oikonomou P, Papadoulis N, Panayiotidis P, Vrakidou E, Tsezou A. Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma. Leuk Lymphoma 2007;48:2196-203.
94. Gu ZJ, Costes V, Lu ZY, Zhang XG, Pitard V, Moreau JF, Bataille R, Wijdenes J, Rossi JF, Klein B. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood 1996;88:3972-86.
95. Hoffmann SC, Stanley EM, Darrin CE, Craighead N, DiMercurio BS, Koziol DE, Harlan DM, Kirk AD, Blair PJ. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 2001;72:1444-50.
96. Zheng C, Huang D, Liu L, Wu R, Bergenbrant GS, Osterborg A, Björkholm M, Holm G, Yi Q, Sundblad A. Interleukin-10 gene promoter polymorphisms in multiple myeloma. Int J Cancer 2001;95:184-8.
97. Mazur G, Bogunia-Kubik K, Wrobel T, Karabon L, Polak M, Kuliczkowski K, Lange A. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett 2005;96:241-6.
98. Ray DM, Bernstein SH, Phipps RP. Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands. Clin Immunol 2004;113:203-13.
99. Luan Y, Xu W. The function of the selective inhibitors of cyclooxygenase 2. Mini Rev Med Chem 2006;6:1375-81.
100. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000;268:178-82.
101. Gonzalez-Periz A, Claria J. New approaches to the modulation of the cyclooxygenase-2 and 5-lipoxygenase pathways. Curr Top Med Chem 2007;7:297-309.
102. Cetin M, Buyukberber S, Demir M, et al. Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival. Am J Hematol 2005;80:169-73.
103. Ladetto M, Vallet S, Trojan A, et al. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 2005;105:4784-91.
104. Sanak M, Szczeklik W, Szczeklik A. Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma. J Allergy Clin Immunol 2005;116:221-3.
105. Zheng C, Huang D, Liu L, Bjorkholm M, Holm G, Yi Q, Sundblad A. Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma. Br J Haematol 2001;112:216-8.
106. Lee KM, Baris D, Zhang Y, et al. Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut. Am J Hematol 2010;85:560-3.
107. Purdue MP, Lan Q, Menashe I, et al. Variation in innate immunity genes and risk of multiple myeloma. Hematol Oncol 2011;29:42-6.
108. Van Ness B, Ramos C, Haznadar M, et al. Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med 2008;6:26.
109. Ortega MM, Nascimento H, Costa FF, Teori MT, Lima CS. A polymorphism in the angiogenesis inhibitor, endostatin, in multiple myeloma. Leuk Res 2003;27:93-4.
110. Au WY, Fung A, Wong KF, Chan CH, Liang R. Tumor necrosis factor alpha promoter polymorphism and the risk of chronic lymphocytic leukemia and myeloma in the Chinese population. Leuk Lymphoma 2006;47:2189-93.
111. Paneesha S, Starczynski J, Pepper C, Delgado J, Hooper L, Fegan C, Pratt G. The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers and survival in multiple myeloma. Leuk Lymphoma 2006;47:281-4.
112. Pemberton NC, Paneesha S, Hiller L, Starczynski J, Hooper L, Pepper C, Pratt G, Fegan C. The SDF-1G > A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemia. Leuk Lymphoma 2006;47:1239-44.
113. Ostrovsky O, Korostishevsky M, Levite I, Leiba M, Galski H, Vlodavsky I, Nagler A. Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies. Leukemia 2007;21:2296-303.